{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-035701","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2022-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.959892+00:00","generated_at":"2026-06-22T23:07:02.291514+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ARCA biopharma Q3 net loss narrows to $2.3M; strategic review with workforce reduction","bullets":["Net loss of $2.3M ($0.16/sh) narrowed from $4.7M ($0.33/sh) in Q3 2021.","Cash $43.9M as of Sep 30, 2022; sufficient to fund operations through end of 2023.","Workforce reduction with ~$0.8M restructuring charges recorded in Q3 2022.","Strategic review with Ladenburg Thalmann; evaluating acquisition, merger, or other options.","R&D expenses fell to $1.0M from $3.4M due to completion of rNAPc2 Phase 2b trial enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-035701","json":"https://secwatch.observer/filing/0001564590-22-035701.json","markdown":"https://secwatch.observer/filing/0001564590-22-035701.md","text":"https://secwatch.observer/filing/0001564590-22-035701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/0001564590-22-035701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/abio-8k_20221028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:07:02.291514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb5b049363116d797bae37e475a5b87c17c901fe","claim":"Oruka Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"Net loss for the quarter ended September 30, 2022 was $2.3 million, or $0.16 per basic and diluted share, compared to $4.7 million, or $0.33 per basic and diluted share in the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/0001564590-22-035701-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eb5b049363116d797bae37e475a5b87c17c901fe","claim":"Oruka Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On October 28, 2022, ARCA biopharma, Inc., or ARCA, issued a press release reporting financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000156459022035701/0001564590-22-035701-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}